Float Short %

14.49

Margin Of Safety %

Put/Call OI Ratio

0.89

EPS Next Q Diff

0.02

EPS Last/This Y

-0.47

EPS This/Next Y

0.14

Price

2.14

Target Price

9.43

Analyst Recom

1.33

Performance Q

-30.16

Upside

-1,233.8%

Beta

1.96

Ticker: GOSS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	GOSS	2.7	0.54	0.77	261316
2026-01-26	GOSS	2.65	0.55	3.47	276235
2026-01-27	GOSS	2.63	0.58	0.56	282300
2026-01-28	GOSS	2.56	0.59	0.54	290310
2026-01-29	GOSS	2.41	0.61	1.11	304180
2026-01-30	GOSS	2.28	0.59	1.73	313049
2026-02-02	GOSS	2.47	0.60	0.47	317373
2026-02-03	GOSS	2.67	0.62	5.42	342923
2026-02-04	GOSS	2.45	0.66	1.47	353539
2026-02-05	GOSS	2.43	0.74	0.78	397387
2026-02-06	GOSS	2.27	0.73	1.02	431714
2026-02-09	GOSS	2.25	0.74	1.49	440458
2026-02-10	GOSS	2.35	0.78	0.94	453286
2026-02-11	GOSS	2.35	0.81	0.11	480060
2026-02-12	GOSS	2.33	0.81	2.62	485196
2026-02-13	GOSS	2.29	0.83	1.07	490325
2026-02-17	GOSS	2.16	0.85	2.11	511343
2026-02-18	GOSS	2.16	0.88	3.22	523846
2026-02-19	GOSS	2.1	0.89	2.03	532949
2026-02-20	GOSS	2.14	0.89	0.65	538294
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	GOSS	2.70	-29.5	124.9	-0.72
2026-01-26	GOSS	2.65	-29.5	124.0	-0.72
2026-01-27	GOSS	2.64	-29.5	123.8	-0.72
2026-01-28	GOSS	2.57	-29.5	124.2	-0.72
2026-01-29	GOSS	2.42	-29.5	124.8	-0.72
2026-01-30	GOSS	2.28	-23.8	124.9	-0.72
2026-02-02	GOSS	2.48	-23.8	121.5	-0.72
2026-02-03	GOSS	2.67	-23.8	121.8	-0.72
2026-02-04	GOSS	2.45	-23.8	-	-0.72
2026-02-05	GOSS	2.43	-23.8	-	-0.72
2026-02-06	GOSS	2.27	-23.8	-	-0.72
2026-02-09	GOSS	2.26	-23.8	-	-0.72
2026-02-10	GOSS	2.34	-23.8	-	-0.72
2026-02-11	GOSS	2.35	-23.8	-	-0.72
2026-02-12	GOSS	2.33	-23.8	-	-0.72
2026-02-13	GOSS	2.30	-23.8	-	-0.72
2026-02-17	GOSS	2.16	-23.8	-	-0.72
2026-02-18	GOSS	2.16	-23.8	-	-0.72
2026-02-19	GOSS	2.11	-23.8	-	-0.72
2026-02-20	GOSS	2.14	-23.8	-	-0.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	GOSS	0.06	2.28	13.04
2026-01-26	GOSS	0.06	2.03	13.04
2026-01-27	GOSS	0.06	2.03	13.04
2026-01-28	GOSS	0.06	2.03	13.64
2026-01-29	GOSS	0.06	2.03	13.64
2026-01-30	GOSS	0.06	2.03	13.64
2026-02-02	GOSS	0.06	1.97	13.64
2026-02-03	GOSS	0.06	1.97	13.64
2026-02-04	GOSS	0.06	1.97	13.64
2026-02-05	GOSS	0.06	1.97	13.64
2026-02-06	GOSS	0.06	1.97	13.64
2026-02-09	GOSS	0.06	0.50	13.64
2026-02-10	GOSS	0.06	0.50	13.64
2026-02-11	GOSS	0.06	0.50	14.49
2026-02-12	GOSS	0.06	0.50	14.49
2026-02-13	GOSS	0.06	0.50	14.49
2026-02-17	GOSS	0.06	2.83	14.49
2026-02-18	GOSS	0.06	2.83	14.49
2026-02-19	GOSS	0.06	2.83	14.49
2026-02-20	GOSS	0.06	2.83	14.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

0.06

Institutional Transactions

2.83

Beta

1.96

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.9

Max Drawdown 5-Year %

-96.8

Target Price

9.43

P/E

Forward P/E

PEG

P/S

11.19

P/B

P/Free Cash Flow

EPS

-0.69

Average EPS Est. Cur. Y

-0.72

EPS Next Y. (Est.)

-0.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-354.5

Relative Volume

1.8

Return on Equity vs Sector %

160.7

Return on Equity vs Industry %

178.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Gossamer Bio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 144

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today

news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance

stock history GOSS – Gossamer Bio, Inc. invest stock market

stock prices GOSS premarket after hours

ticker GOSS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GOSS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y